Drug Intended for the Treatment of Raynaud's Phenomena, Secondary to Systemic Sclerosis SAN DIEGO, April 13, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today its filing with the U.S. Food & Drug Administration ("FDA") requesting orphan drug designation for RayVa™, the Company's drug candidate indicated for the treatment of Raynaud's
A drug used to treat erectile dysfunction, is showing promise for patients suffering from a rare blood condition. Raynaud’s disease is a condition that causes discoloration of fingers and toes. When people with Raynaud’s disease are exposed to the cold, their blood vessels close causing their fingers or toes to turn white or red. Some doctors believe
Two videos from CBS affiliate stations - New York and Philadelphia - talk about the use of Botox and Viagra for Raynaud's. While both treatments are promising, more clinical support is still required to convince the medical community and the insurance industry to apply these treatments on a broader scale to Raynaud's sufferers. http://newyork.cbslocal.com/2011/01/28/healthwatch-cold-hands/ http://philadelphia.cbslocal.com/category/watch-listen/video-on-demand/?autoStart=true&topVideoCatNo=default&clipId=5499257&flvUri=&partnerclipid=
Biofeedback therapy for Raynaud's has shown to be highly effective in some cases with reports indicating 80-90% of patients with improved circulation.
